Archive

ISSUE 20 - 22

Previous | Next

      April - December 2014, Volume 9 No 20 - 22

About the Cover

The antibacterial and antifungal activities of extracts (10, 20, 30 and 40 μg/ml) of Solanum erianthum were tested against five bacterial and five fungal strains. The antimicrobial activity was determined in the extracts using agar disc diffusion method Zone of inhibition of extracts were compared with that of standards like ampicillin and chloramphenicol for antibacterial activity and griseofulvin for antifungal activity. The results showed that the remarkable inhibition of the bacterial growth was shown against the tested organisms. Hence, these plants can be used to discover bioactive natural products that may serve as leads in the development of new pharmaceuticals research activities (Ref: Sirajudeen J, Muneer Ahamath J. Evaluation of Antibacterial and Antifungal activity of medicinal plant Solanum erianthum. Drug Discovery, 2014, 9(22), 35-39), (Image: cals-cf.calsnet.arizona.edu).




DRUG DISCOVERY OF THE MONTH

Top

Novel Drugs for Hepatitis C: a step forward to Injection-Free Therapy

Vidhya V

Hepatitis C is the most common chronic blood-borne infection in the U.S. and is one of the leading causes of liver disease and liver cancer. Hepatitis C can be either “acute” or “chronic.” For most people, acute infection leads to chronic infection. Chronic hepatitis C is a serious disease than can result in long-term health problems, or even death. People who inject drugs can benefit from hepatitis C prevention efforts and antiviral treatment, but comprehensive programs may be needed to help overcome a variety of challenges, according to a special supplement of Clinical Infectious Diseases entitled "Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs: Moving the Agenda Forward." "HCV treatment is safe and effective among people who inject drugs [PWID]. In February, the U.S. Department of Health and Human Services (HHS) noted the rising epidemic of hepatitis C virus among young people aged 15-30 who inject drugs, calling attention to an increasingly serious issue nationwide.

Drug Discovery, 2014, 9(20), 8-9

Full Text | PDF

FDA APPROVED DRUGS

Top

FDA approved drugs – December 2013

Vidhya V

Anoro Ellipta is specifically indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema. It is supplied as a powder formulation for inhalation. The recommended dose is one inhalation of Anoro Ellipta once daily. Anoro Ellipta should be administered at the same time every day. The dose should not exceed one dose every 24 hours.

Drug Discovery, 2014, 9(20), 10-12

Full Text | PDF

FDA approved drugs – January 2014

Vidhya V

Farxiga (dapagliflozin) is an orally active sodium glucose cotransporter type 2 (SGLT-2) inhibitor. Inhibiting SGLT2 activity modulates reabsorption of glucose in the kidney, resulting in excretion of glucose in the urine. It is specifically indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus. It is supplied as a tablet for oral administration. The recommended starting dose is 5 mg once daily, taken in the morning, with or without food. The dose can be increased to 10 mg once daily in patients tolerating Farxiga who require additional glycemic control. Renal function should be assessed before initiating Farxiga. Do not initiate Farxiga if eGFR is below 60 mL/min/1.73 m2. Farxiga should be discontinued if eGFR falls persistently below 60 mL/min/1.73 m2.

Drug Discovery, 2014, 9(20), 13-14

Full Text | PDF

FDA approved drugs – February 2014

Vidhya V

Myalept is specifically indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. It is supplied as a solution for subcutaneous injection.

Drug Discovery, 2014, 9(20), 15-17

Full Text | PDF

COMMUNICATION

Top

Thasus gigas Burn: a new treatment for diabetes or nutrimental culture

Echavarría Flores Montserrat, García Torres María Elena, Calderón Ordoñez Marisela Belem, Olvera Luna Alba Grisel, Jesús Carlos Ruvalcaba Ledezma

Determining the benefits that people, who suffer from diabetes type II, obtain by eating the bedbugs “Xohues” or “shamues” (Thasus gigas). In addition, this project aims to diagnose how this food intake affects medical treatments. An exploratory study was conducted; surveys among residents of the community of Santiago Tulantepec and residents of the city of Actopan, both in the state of Hidalgo were asked to participate in a survey. The survey mentioned was applied to 50 people from both populations. It is important to mention that the participants suffered from Diabetes Mellitus type II and the investigation aimed to investigate the effects of Shamues or xohues intake and their use as medical treatment to diabetes.

Drug Discovery, 2014, 9(20), 18-19

Full Text | PDF

PERSPECTIVE

Top

Rumex crispus L. – a plant of traditional value

Archana Pareek, Ashwani Kumar

Wetlands are areas of standing water that support aquatic plants & provide a unique habitat for several plant of economic importance. Present papers deal some of the traditional values of Rumex crispus L. (family polygonaceae) a wetland plant by local community of India. This paper is first report from the Rajasthan.

Drug Discovery, 2014, 9(20), 20-23

Full Text | PDF

RESEARCH

Top

Virtual Screening Analysis for Drug Designing against Precursor Protein of Alzheimer’s disease

Anupam Singh, Viswanath Rana, Sakshi Choudhari, Pankaj Panday, Ashwani Kumar Singh

Alzheimer’s disease is a neurodegenerative disorder. In this type of disease there is loss of structures or the function of neurons,in which Amyloid plaques are formed by aggregation of Aβpeptide. Aβpeptides are generated by successive cleavages of amyloid precursor protein (APP) by βand γsecretase enzyme.In recent years, several approaches aimed at inhibiting disease progression have advanced to clinical trials. Therefore we have taken the Alzheimer’s amyloid beta-protein cause for the disease.To inhibit the activity of this protein we have taken many inhibitory molecules from the various sources and analyze binding interaction to target protein on the basis of docking energy and after this, predict the effects of therapeutic molecules on human body. There is substantial in-silico data indicating that therapeutic molecules have antioxidant, anti-inflammatory, and anti-amyloid activity.

Drug Discovery, 2014, 9(21), 27-31

Full Text | PDF

Evaluation of Antibacterial and Antifungal activity of medicinal plant Solanum erianthum

Sirajudeen J, Muneer Ahamath J

The antibacterial and antifungal activities of extracts (10, 20, 30 and 40 μg/ml) of Solanum erianthum were tested against five bacterial and five fungal strains. The antimicrobial activity was determined in the extracts using agar disc diffusion method Zone of inhibition of extracts were compared with that of standards like ampicillin and chloramphenicol for antibacterial activity and griseofulvin for antifungal activity. The results showed that the remarkable inhibition of the bacterial growth was shown against the tested organisms. Hence, these plants can be used to discover bioactive natural products that may serve as leads in the development of new pharmaceuticals research activities.

Drug Discovery, 2014, 9(22), 35-39

Full Text | PDF